AI Article Synopsis
- Convalescent plasma (CP) therapy was studied for its effectiveness in treating COVID-19, specifically looking at neutralizing antibody (NAb) levels in both donors and patients.
- The study involved hospitalized COVID-19 patients receiving CP transfusions and monitored their NAb and antibody levels over 14 days, finding initially low NAb titers with no immediate impact post-transfusion.
- Results showed that while patients developed detectable NAb levels over time, the actual CP transfusion did not enhance these levels, suggesting the need for better screening of donors for higher NAb titers.
Article Abstract
Background: Convalescent plasma (CP) is a potentially important therapy for coronavirus disease 2019 (COVID-19). However, knowledge regarding neutralizing antibody (NAb) titers in donor plasma and their impact in patients with acute COVID-19 remains largely undetermined. We measured NAb titers in CP and in patients with acute COVID-19 before and after transfusion through the traditional Food and Drug Administration investigational new drug pathway.
Methods: We performed a single-arm interventional trial measuring NAb and total antibody titers before and after CP transfusion over a 14-day period in hospitalized patients with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 infection.
Results: NAb titers in the donor CP units were low (<1:40 to 1:160) and had no effect on recipient neutralizing activity 1 day after transfusion. NAb titers were detected in 6 of 12 patients on enrollment and in 11 of 12 at ≥2 time points. Average titers peaked on day 7 and declined toward day 14 (P = .004). Nab titers and immunoglobulin G levels were correlated in donor plasma units (ρ = 0.938; P < .001) and in the cumulative patient measures (ρ = 0.781; P < .001).
Conclusions: CP infusion did not alter recipient NAb titers. Prescreening of CP may be necessary for selecting donors with high titers of neutralizing activity for infusion into patients with COVID-19.
Clinical Trials Registration: NCT04434131.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454720 | PMC |
| http://dx.doi.org/10.1093/infdis/jiaa505 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Current HIV prophylactic vaccines evaluate HIV Env as purified proteins. CD40.HIVRI.
View Article and Find Full Text PDFComprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer.
Vaccine
December 2024
Monash University, Department of Oncology, School of Clinical Sciences, Melbourne, VIC, Australia; University of Bern, Department of Clinical Research (Medicine), Bern, Switzerland; University Cancer Centre, Bern, Switzerland.
Background: The COVID-19 pandemic has significantly impacted people with cancer. Initial vaccine studies excluded patients with malignancy. Immunocompromised individuals remain vulnerable to SARS-CoV-2, necessitating detailed understanding of vaccine response.
View Article and Find Full Text PDFImmune Evasion, Cell-Cell Fusion, and Spike Stability of the SARS-CoV-2 XEC Variant: Role of Glycosylation Mutations at the N-terminal Domain.
bioRxiv
November 2024
Center for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA.
Article Synopsis
- SARS-CoV-2 is evolving, resulting in new variants like XEC, which has specific mutations (T22N and F59S) in the spike protein that affect how the virus interacts with neutralizing antibodies.
- The study analyzed immune responses from different vaccinated groups and found that XEC had significantly lower neutralization levels due to the F59S mutation, but removing certain glycosylation sites could restore these levels.
- The research highlights that mutations in the N-terminal domain of the spike protein play a crucial role in the virus's ability to evade the immune system and change its structural properties.
Neutralizing Antibody-Mediated Protection from Prior Delta Variant Infection Against Omicron BA.5 Sub-Lineage Reinfection One Year Later: A Prospective Cohort Study.
Vaccines (Basel)
October 2024
Department of Acute Infectious Disease Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.
Background: Previous SARS-CoV-2 infection provides some level of protection against reinfection. However, few studies have evaluated the neutralizing antibody (NAb) response after Delta variant infection and its ability to prevent reinfection with Omicron BA.5 one year later.
View Article and Find Full Text PDFImmunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis.
Front Immunol
November 2024
Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States.
Background: Development of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) to monoclonal antibodies may adversely impact pharmacokinetics, efficacy, and/or safety.
Objective: To describe incidence, titer, and persistence of dupilumab ADAs and NAbs, and their effects on pharmacokinetics, efficacy, and safety in patients with atopic dermatitis (AD).
Methods: This analysis included seven phase 3 randomized, placebo-controlled (N=2,992) and two long-term open-label extension (N=2,287) trials of subcutaneous dupilumab in adults and pediatric patients with moderate-to-severe AD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!